extract: 2024-11-01-aspe-medicare-anti-obesity-medication-coverage
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
afc7de403f
commit
849a626ec9
5 changed files with 58 additions and 1 deletions
|
|
@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca
|
|||
|
||||
The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
The GLP-1 Medicare coverage debate provides a quantified example: CBO's $35B cost estimate vs. ASPE's $715M savings calculation represents a $35.7B methodological divergence on the same policy. ASPE projects 38,950 CV events avoided and 6,180 deaths avoided over 10 years from broad semaglutide access, but these downstream savings are not fully captured in CBO's budget scoring framework.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
|
|||
- Nature Medicine: additive benefits with SGLT2 inhibitors
|
||||
- First GLP-1 to receive FDA indication for CKD in T2D patients
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
ASPE quantifies the cardiovascular benefit at population scale: broad Medicare semaglutide access would avoid 38,950 CV events and 6,180 deaths over 10 years. The proposed eligibility criteria require comorbidities (CVD history, heart failure, CKD, prediabetes) rather than BMI alone, targeting the population where multi-organ protection generates maximum value.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
- FDA indication expansion to T2D patients with CKD (2024)
|
||||
- Dialysis cost benchmark: $90K+/year per patient
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
Medicare eligibility criteria for GLP-1 coverage include CKD as a qualifying comorbidity, and ASPE's net savings calculation ($715M over 10 years) incorporates avoided dialysis costs as a major component of the downstream value. Approximately 10% of Medicare beneficiaries would be eligible under the proposed comorbidity-based criteria.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,25 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md:set_created:2026-03-15",
|
||||
"federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md:stripped_wiki_link:GLP-1-receptor-agonists-are-the-largest-therapeutic-category"
|
||||
],
|
||||
"rejections": [
|
||||
"federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2024-11-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: policy
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,13 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve
|
|||
EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
|
||||
|
||||
flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- CBO estimates Medicare GLP-1 coverage would cost $35 billion over 2026-2034
|
||||
- ASPE calculates net savings of $715 million over 10 years (range: $412M to $1.04B)
|
||||
- Annual Part D cost increase projected at $3.1-6.1 billion
|
||||
- Broad semaglutide access would avoid 38,950 CV events over 10 years
|
||||
- Broad semaglutide access would avoid 6,180 deaths over 10 years
|
||||
- Approximately 10% of Medicare beneficiaries would be eligible under proposed criteria
|
||||
- Eligibility requires comorbidities: CVD history, heart failure, CKD, or prediabetes
|
||||
|
|
|
|||
Loading…
Reference in a new issue